Compare TransMedics Group Inc (TMDX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Tripadvisor Inc Common Stock — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while Tripadvisor Inc Common Stock trades at $13.82 (market cap $1.68B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | TRIP | |
|---|---|---|
Market Cap | $2.54B | $1.68B |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $19.14 |
52-Week Low | $61.99 | $9.24 |
Enterprise Value | $2.94B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Tripadvisor (TRIP) trades at $13.8, down 5.35% over 24 hours. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators are neutral. Fundamentally, revenue grew to $1.89B in 2025 with a net income margin of 0.99%, but recent earnings misses and a high P/E of 131.09 raise valuation concerns. The recent $700M sale of TheFork to American Express simplifies the business and provides a cash infusion.
Outlook is mixed: the sale of TheFork and focus on core experiences offer strategic clarity, but stiff competition and macroeconomic pressures pose risks. Analyst consensus is a 'Hold' with a $13.87 price target, slightly above the current price, indicating limited near-term upside amid cautious sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
